adaura trial: osimertinib for early stage egfr nsclc - 2022 program: targeted therapies forum
Published 2 years ago • 194 plays • Length 2:06Download video MP4
Download video MP3
Similar videos
-
2:30
acquired resistance to osimertinib in egfr nsclc - 2022 program: targeted therapies forum - english
-
3:20
egfr mutated nsclc disease progression on osimertinib - 2022 program: targeted therapies forum
-
5:54
key points from the adaura trial: osimertinib - targeted therapies in lung cancer 2023
-
4:22
what is egfr in lung cancer? - 2022 program: targeted therapies forum
-
6:06
the adaura trial: the effect on egfr treatment - targeted therapies in lung cancer 2023
-
3:55
disease progression on lorlatinib or osimertinib - 2022 program: targeted therapies forum
-
4:08
what if osimertinib stops working? - 2022 program: targeted therapies forum
-
58:19
the implications of recent datasets for the current and future management of nsclc egfr mutations
-
5:12
adaura trial: tagrisso & resectable egfr - leading developments & current questions in lung cancer
-
1:47
amivantamab and lazertinib in egfr met disease - 2022 program: targeted therapies forum - english
-
6:00
the adaura trial: 2023 updates - targeted therapies in lung cancer 2023
-
5:42
osimertinib and the flaura trial
-
6:26
the adaura trial: the effect on egfr treatment
-
6:14
key points from the adaura trial: osimertinib
-
16:41
asco lung cancer roundtable - trial updates in nsclc - adaura trial and post surgery egfr mutation
-
11:41
the adaura trial: flaws and results - leading developments & current questions in lung cancer
-
3:14
advancements of targeted therapy for egfr mutations in nsclc
-
3:24
2020 ttf egfr session qa panel srt with osimertinib (tagrisso) first line, stable disease
-
1:43
egfr and pneumonitis: treatments other than erlotinib - 2022 program: targeted therapies forum